Clinical Trial Update: Dexmedetomidine on Postoperative Cognitive Dysfunction and Serum Tau-217 Protein. [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating dexmedetomidine for postoperative cognitive dysfunction and serum Tau-217 protein, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment

Drugs mentioned

• Dexmedetomidine (Dexmedetomidine)

Snippet

Sponsor: Minia University Hospital | Conditions: Cognitive Impairment | Phase 4 | Status: RECRUITING